272 related articles for article (PubMed ID: 20398022)
1. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy.
Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J
Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
7. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
8. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
9. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?
Buch MH; Conaghan PG; Quinn MA; Bingham SJ; Veale D; Emery P
Ann Rheum Dis; 2004 Oct; 63(10):1344-6. PubMed ID: 15033655
[TBL] [Abstract][Full Text] [Related]
10. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
11. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
12. The role of tumor necrosis factor antagonism in clinical practice.
Keystone EC
J Rheumatol Suppl; 1999 May; 57():22-8. PubMed ID: 10328139
[TBL] [Abstract][Full Text] [Related]
13. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
[TBL] [Abstract][Full Text] [Related]
14. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
[TBL] [Abstract][Full Text] [Related]
15. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
17. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
[TBL] [Abstract][Full Text] [Related]
18. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
[TBL] [Abstract][Full Text] [Related]
20. Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis.
Furst DE; Keystone E; Maini RN; Smolen JS
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():50-3. PubMed ID: 10646494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
